Gouri M Koduri1, Nicola J Gullick2, Fiona Hayes1, Shirish Dubey2, Chetan Mukhtyar3. 1. Rheumatology Department, Southend University Hospital, Westcliff-on-Sea. 2. Rheumatology Department, University Hospitals Coventry & Warwickshire NHS Trust, Coventry. 3. Rheumatology Department, Norfolk and Norwich University Hospital, Norwich, UK.
Abstract
OBJECTIVE: Longer life expectancy has resulted in people living with an increasing number of co-morbidities. The average individual with inflammatory arthritis has two co-morbidities, which contribute to higher mortality, poorer functional outcomes and increased health-care utilization and cost. A number of studies have investigated the prevalence of co-morbidities, whereas this study was designed to look at patient perspectives. METHODS: The study comprised two parts: a patient questionnaire and an interview. Individuals with physician-verified inflammatory arthritis along with one or more Charlson co-morbidities were invited to participate. In-depth data were obtained by interviews with 12 willing participants. RESULTS: One hundred and forty-six individuals were recruited; 50 (35%) had one co-morbidity, 69 (48%) had two and 25 (17%) had more than four co-morbidities. Seventy-seven individuals (53%) reported that co-morbidities affected their health as much as their arthritis, and 82 (56%) reported dependence on others for activities of daily living. Lack of education was highlighted by 106 (73%) participants. Qualitative data provided further support for the challenges, with participants highlighting the lack of time to discuss complex or multiple problems, with no-one coordinating their care. This, in turn, led to polypharmacy and insufficient discussion around drug and disease interactions, complications and self-help measures. CONCLUSION: This study highlights the challenges for individuals with inflammatory arthritis who suffer with multiple co-morbidities. The challenges result from limited resources or support within the current health-care environments. Individuals highlighted the poor quality of life, which is multifactorial, and the need for better educational strategies and coordination of care to improve outcomes.
OBJECTIVE: Longer life expectancy has resulted in people living with an increasing number of co-morbidities. The average individual with inflammatory arthritis has two co-morbidities, which contribute to higher mortality, poorer functional outcomes and increased health-care utilization and cost. A number of studies have investigated the prevalence of co-morbidities, whereas this study was designed to look at patient perspectives. METHODS: The study comprised two parts: a patient questionnaire and an interview. Individuals with physician-verified inflammatory arthritis along with one or more Charlson co-morbidities were invited to participate. In-depth data were obtained by interviews with 12 willing participants. RESULTS: One hundred and forty-six individuals were recruited; 50 (35%) had one co-morbidity, 69 (48%) had two and 25 (17%) had more than four co-morbidities. Seventy-seven individuals (53%) reported that co-morbidities affected their health as much as their arthritis, and 82 (56%) reported dependence on others for activities of daily living. Lack of education was highlighted by 106 (73%) participants. Qualitative data provided further support for the challenges, with participants highlighting the lack of time to discuss complex or multiple problems, with no-one coordinating their care. This, in turn, led to polypharmacy and insufficient discussion around drug and disease interactions, complications and self-help measures. CONCLUSION: This study highlights the challenges for individuals with inflammatory arthritis who suffer with multiple co-morbidities. The challenges result from limited resources or support within the current health-care environments. Individuals highlighted the poor quality of life, which is multifactorial, and the need for better educational strategies and coordination of care to improve outcomes.
Authors: Anna Moltó; Adrien Etcheto; Désirée van der Heijde; Robert Landewé; Filip van den Bosch; Wilson Bautista Molano; Ruben Burgos-Vargas; Peter P Cheung; Eduardo Collantes-Estevez; Atul Deodhar; Bassel El-Zorkany; Shandor Erdes; Jieruo Gu; Najia Hajjaj-Hassouni; Uta Kiltz; Tae-Hwan Kim; Mitsumasa Kishimoto; Shue-Fen Luo; Pedro M Machado; Walter P Maksymowych; José Maldonado-Cocco; Helena Marzo-Ortega; Carlo-Maurizio Montecucco; Salih Ozgoçmen; Floris van Gaalen; Maxime Dougados Journal: Ann Rheum Dis Date: 2015-10-21 Impact factor: 19.103
Authors: Jesper Lindhardsen; Ole Ahlehoff; Gunnar Hilmar Gislason; Ole Rintek Madsen; Jonas Bjerring Olesen; Christian Torp-Pedersen; Peter Riis Hansen Journal: Ann Rheum Dis Date: 2011-03-09 Impact factor: 19.103
Authors: Ingrid Demmelmaier; Pernilla Åsenlöf; Patrick Bergman; Birgitta Nordgren; Christina H Opava Journal: Rheumatol Int Date: 2017-01-25 Impact factor: 2.631
Authors: Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay Journal: Ann Rheum Dis Date: 2013-10-04 Impact factor: 19.103